AgomAb Therapeutics NV
Research AgomAb Therapeutics NV (AGMB) on Bullrun: market cap USD 877.60M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAGMB
- ExchangeNASDAQ
- CountryBelgium
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 877.60M
- Financial periodQ4 2025
- Net income-USD 17.40M
- Free cash flow-USD 13.18M
Valuation Snapshot
latest market cap is USD 877.60M.
About AgomAb Therapeutics NV
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials;
Frequently asked questions
What is AgomAb Therapeutics NV's market cap?
AgomAb Therapeutics NV's market capitalization is USD 877.60M.
What does AgomAb Therapeutics NV do?
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States.